Permanent URI for this collection
Browse
Recent Submissions
Publication Epilepsy related multimorbidity, polypharmacy and risks in adults with intellectual disabilities: a national study(Springer, 2022-01-04) Sun, James; Perera, Bhathika; Henley, William; Angus-Leppan, Heather; Sawhney, Indermeet; Watkins, Lance; Purandare, Kiran; Eyeoyibo, Mogbeyiteren; Scheepers, Mark; Lines, Geraldine; Winterhalder, Robert; Ashby, Samantha; De Silva, Ravi; Miller, Jonjo; Philpott, David; Ashwin, Chris; Howkins, Joshua; Slater, Harriet; Medhurst, David; Shankar, Rohit; Scheepers, Mark; Medical and DentalBackground: A quarter of people with Intellectual Disability (ID) in the UK have epilepsy compared to 0.6% in the general population and die much younger. Epilepsy is associated with two-fifths of all deaths with related polypharmacy and multi-morbidity. Epilepsy research on this population has been poor. This study describes real-world clinical and risk characteristics of a large cohort across England and Wales. Methods: A retrospective multi-centre cohort study was conducted. Information on seizure characteristics, ID severity, relevant co-morbidities, psychotropic and antiseizure drugs (ASDs), SUDEP and other risk factors was collected across a year. Results: Of 904 adults across 10 centres (male:female, 1.5:1), 320 (35%) had mild ID and 584 (65%) moderate-profound (M/P) ID. The mean age was 39.9 years (SD 15.0). Seizures were more frequent in M/P ID (p < 0.001). Over 50% had physical health co-morbidities, more in mild ID (p < 0.01). A third had psychiatric co-morbidity and a fifth had an underlying genetic disorder. Autism Spectrum Disorder was seen in over a third (37%). Participants were on median two ASDs and overall, five medications. Over quarter were on anti-psychotics. Over 90% had an epilepsy review in the past year but 25% did not have an epilepsy care plan, particularly those with mild ID (p < 0.001). Only 61% had a documented discussion of SUDEP, again less likely with mild ID or their care stakeholders (p < 0.001). Conclusions: Significant levels of multi-morbidity, polypharmacy and a lack of systemised approach to treatment and risk exist. Addressing these concerns is essential to reduce premature mortality.Publication Mortality risk in adults with intellectual disabilities and epilepsy: an England and Wales case-control study(Springer, 2023-04-06) Sun, James; Watkins, Lance; Henley, Williams; Laugharne, Richard; Angus-Leppan, Heather; Sawhney, Indermeet; Moghaddassian Shahidi, Meissam; Purandare, Kiran; Eyeoyibo, Mogbeyiteren; Scheepers, Mark; Lines, Geraldine; Winterhalder, Robert; Perera, Bhathika; Hyams, Benjamin; Ashby, Samantha; Shankar, Rohit; Scheepers, Mark; Medical and DentalBackground: People with epilepsy (PWE) and people with intellectual disabilities (ID) both live shorter lives than the general population and both conditions increase the risk of death further. We aimed to measure associations between certain risk factors for death in PWE and ID. Methods: A retrospective case-control study was conducted in ten regions in England and Wales. Data were collected on PWE registered with secondary care ID and neurology services between 2017 and 2021. Prevalence rates of neurodevelopmental, psychiatric and medical diagnoses, seizure frequency, psychotropic and antiseizure medications (ASM) prescribed, and health activity (epilepsy reviews/risk assessments/care plans/compliance etc.) recorded were compared between the two groups. Results: 190 PWE and ID who died were compared with 910 living controls. People who died were less likely to have had an epilepsy risk assessment but had a greater prevalence of genetic conditions, older age, poor physical health, generalized tonic-clonic seizures, polypharmacy (not ASMs) and antipsychotic use. The multivariable logistic regression for risk of epilepsy-related death identified that age over 50, medical condition prevalence, antipsychotic medication use and the lack of an epilepsy review in the last 12 months as associated with increased risk of death. Reviews by psychiatrists in ID services was associated with a 72% reduction in the odds of death compared neurology services. Conclusions: Polypharmacy and use of antipsychotics may be associated with death but not ASMs. Greater and closer monitoring by creating capable health communities may reduce the risk of death. ID services maybe more likely to provide this holistic approach.Publication Who and what supports systemic working in a learning disabilities context?(British Psychological Society, 2024-02-14) Ramsey, Bethan; Baum, Sandra; Shilling, Hannah; Bodicoat, Anna; Zujus, Arnas; Cooper, Becky; Daynes, Shona; Fuchs, Karin; Haydon-Laurelut, Mark; Darbyshire, Laura; Morris, Lisa; Carrington, Laura; Bucher, Katharina; Yildiran, Hatice; Robbins, Lorna; Shilling, Hannah; Medical and DentalThis article sets out some of the many ways in which systemic working can find a place in Learning Disability (LD) services. It covers ways in which systemic working can influence different aspects of work in an LD service, possibilities for embedding systemic approaches in Positive Behaviour Support (PBS) work in an Enhanced Support Service (ESS), systemic consultation in an LD team, systemic working in a forensic LD service and a specialist LD family therapy service. We hope the article offers a range of ideas which others can draw upon in thinking about their own context, practice and future possibilities.